ArticleJHEP reports : innovation in hepatology2023

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.

Hannah Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.